Home > Insider Trading > Filing (0001610717-24-000014)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1880438	An2 Therapeutics Inc.	ANTX	Pharmaceutical Preparations (2834)	820606654

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1916925	Michael Kevin Krause	C/O An2 Therapeutics, Inc. 1800 El Camino Real, Suite D Menlo Park CA 94027	Chief Strategy Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-02	2,583	$0.42	4,497	No	4	M	Direct
Common Stock	Disposition	2024-01-02	2,583	$20.12	1,914	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2024-01-02	2,583	$0.00	2,583	$0.42

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
52,285		2030-01-22	No	4	M	Direct

Footnotes

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023.
Reflects the adjusted total which includes the purchase of 934 shares under the AN2 Employee Stock Purchase Plan on March 31, 2023.
Reflects the adjusted total which includes the purchase of 980 shares under the AN2 Employee Stock Purchase Plan on September 29, 2023.
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.26. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date.